高危III期黑色素瘤完全切除后辅助伊匹木单抗对比安慰剂的健康相关生活质量(EORTC 18071):一项跨国、随机、双盲、3期试验的次要结局
EORTC 18071试验将951例III期黑色素瘤患者随机分入伊匹木单抗10 mg/kg组(475例)或安慰剂组(476例)。诱导期和诱导后全球健康状况评分组间差异有统计学意义但未达临床相关阈值(10分)。第10周腹泻和失眠评分组间差异超过10分,诱导后无临床相关差异残留。
要点
- 诱导期全球健康状况评分伊匹木单抗组77.32 vs 安慰剂组72.96,差异有统计学意义但未达临床相关。
- 第10周腹泻评分伊匹木单抗组18.17 vs 安慰剂组7.67,失眠评分25.60 vs 15.17,差异均超过10分。
- 尽管毒性增加导致多数患者诱导期停药,总体健康相关生活质量组间相似。
核心结论
- 尽管毒性增加导致多数患者在伊匹木单抗诱导期停药,但EORTC QLQ-C30测量的总体健康相关生活质量组间相似,诱导期或诱导后全球健康状况评分未观察到临床相关差异(10分或以上)。
- 第10周观察到部分症状的临床相关恶化,但诱导后无临床相关差异残留。
- 结合主要分析,伊匹木单抗治疗较安慰剂延长无复发生存期,尽管有研究者报告的3-4级不良事件,健康相关生活质量损伤很小。
研究设计与样本
- EORTC 18071是一项跨国、双盲、随机、3期试验,纳入19个国家 worldwide 的III期皮肤黑色素瘤患者(排除淋巴结转移≤1 mm或转运转移)。
- 参与者通过交互语音应答系统中央随机(1:1)分配接受伊匹木单抗10 mg/kg或安慰剂每3周一次共四剂,然后每3个月一次最多3年。
- 随机化采用最小化技术按疾病分期和地理区域分层。
- 2008年7月10日至2011年8月1日共951例患者随机分配:伊匹木单抗组475例,安慰剂组476例。
- 健康相关生活质量采用EORTC QLQ-C30量表在基线、第4、7、10、24周及此后每12周至2年评估,无论疾病进展。
主要发现
- 完成健康相关生活质量问卷的依从性:基线951例中893例(94%),第24周924例中693例(75%),第108周697例中354例(51%)。
- 诱导期患者平均全球健康状况评分伊匹木单抗组77.32(SD 17.36) vs 安慰剂组72.96(SD 17.82),p=0.00011,差异有统计学意义但未达临床相关。
- 诱导后平均全球健康状况评分伊匹木单抗组76.48(SD 17.52) vs 安慰剂组72.32(SD 18.60),p=0.00067,差异有统计学意义但未达临床相关。
- 平均全球健康状况评分组间差异最大在第7周(安慰剂组77 [SD 19] vs 伊匹木单抗组72 [SD 22])和第10周(77 [SD 20] vs 70 [SD 23])。
- 第10周平均健康相关生活质量评分组间差异超过10分的症状为腹泻(安慰剂组7.67 [SD 17.05] vs 伊匹木单抗组18.17 [SD 28.35])和失眠(15.17 [SD 22.53] vs 25.60 [SD 29.19])。
关键数值与推荐
- 预设的组间10分差异阈值被视为临床相关。
- 主要健康相关生活质量终点为全球健康量表,预设假设为诱导后组间无临床相关差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The EORTC 18071 phase 3 trial compared adjuvant ipilimumab with placebo in patients with stage III melanoma. The primary endpoint, recurrence-free survival, was significantly longer in the ipilimumab group than in the placebo group. Investigator-reported toxic effects of ipilimumab consisted mainly of skin, gastrointestinal, endocrine, and hepatic immune-related adverse events. Adjuvant treatment with ipilimumab in this setting was approved in October, 2014, by the US Food and Drug Administration based on the results of the primary outcome of this trial. Here, we report the results of the secondary endpoint, health-related quality of life (HRQoL), of this trial. METHODS: EORTC 18071 was a multinational, double-blind, randomised, phase 3 trial in patients with stage III cutaneous melanoma (excluding lymph node metastasis ≤1 mm or in-transit metastasis) in 19 countries worldwide. Participants were randomly assigned (1:1) centrally by an interactive voice response system, to receive either ipilimumab 10 mg/kg or placebo every 3 weeks for four doses, then every 3 months for up to 3 years. Using a minimisation technique, randomisation was stratified by disease stage and geographical region. HRQoL was assessed with the EORTC QLQ-C30 quality-of-life instrument at baseline, weeks 4, 7, 10, and 24, and every 12 weeks thereafter up to 2 years, irrespective of disease progression. Results were summarised by timepoint and in a longitudinal manner in the intention-to-treat population. Two summary scores were calculated for each HRQoL scale: the average score reported during induction (ipilimumab or placebo at a dose of 10 mg/kg, administered as one single dose at the start of days 1, 22, 43, and 64-ie, four doses in 3 weeks), and the average score reported after induction. A predefined threshold of a 10 point difference between arms was considered clinically relevant. The primary HRQoL endpoint was the global health scale, with the predefined hypothesis of no clinically relevant differences after induction between groups. This trial is registered with EudraCT, number 2007-001974-10, and ClinicalTrials.gov, number NCT00636168. FINDINGS: Between July 10, 2008, and Aug 1, 2011, 951 patients were randomly assigned to treatment: 475 in the ipilimumab group and 476 in the placebo group. Compliance with completing the HRQoL questionnaire was 893 (94%) of 951 patients at baseline, 693 (75%) of 924 at week 24, and 354 (51%) of 697 at week 108. Patient mean global health scores during (77·32 [SD 17·36] vs 72·96 [17·82]; p=0·00011) and after induction (76·48 [17·52] vs 72·32 [18·60]; p=0·00067) were statistically significantly different between groups but were not clinically relevant. Mean global health scores differed most between the groups at week 7 (77 [SD 19] in the placebo group vs 72 [22] in the ipilimumab group) and week 10 (77 [20] vs 70 [23]). Mean HRQoL scores differed by more than 10 points at week 10 between treatment groups for diarrhoea (7·67 [SD 17·05] for placebo vs 18·17 [28·35] for ipilimumab) and insomnia (15·17 [22·53] vs 25·60 [29·19]). INTERPRETATION: Despite increased toxicity, which led to treatment discontinuation for most patients during the induction phase of ipilimumab administration, overall HRQoL, as measured by the EORTC QLQ-C30, was similar between groups, as no clinically relevant differences (10 points or more) in global health status scores were observed during or after induction. Clinically relevant deterioration for some symptoms was observed at week 10, but after induction, no clinically relevant differences remained. Together with the primary analysis, results from this trial show that treatment with ipilimumab results in longer recurrence-free survival compared with that for treatment with placebo, with little impairment in HRQoL despite grade 3-4 investigator-reported adverse events. FUNDING: Bristol-Myers Squibb.
引用
- Coens C, Suciu S, Chiarion-Sileni V, et al. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncol. 2017. PMID: 28162999. doi:10.1016/S1470-2045(17)30015-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。